Elevance Health (ELV)
NYSE: ELV · Healthcare Plans · Indianapolis, IN
Our rating: Cautious
Call changed from Neutral to Cautious at $414.41, moderate conviction, October 28, 2026.
Breaks if: The cautious view is wrong if free cash flow recovers to $4.8B or above on a trailing twelve-month basis while net margin holds at or above 3.5% through two consecutive quarterly filings — conditions that would signal medical cost pressure has peaked and that reported earnings are being backed by real cash generation. On price, a sustained move above $497 (approximately 20% from here) within the next twelve months, absent those fundamental improvements, would also force a re-examination of this call.
Key figures
| Market value | $85.2B |
|---|---|
| Revenue, last 12 months | $201.8B |
| Net income, last 12 months | $5.1B |
| Free cash flow, last 12 months | $6.5B |
| Price to earnings | 16.6× |
| Free cash flow yield | 7.6% |
| Dividend yield | 1.7% |
| Operating margin | 2.7% |
| Return on equity | 11.6% |
| Beta to the S&P 500 | 0.22 |
| Volatility, annualized | 34.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $51.4B | 1.4% | $6.27 | $1.0B |
| June 30, 2026 | $50.5B | 1.4% | $6.71 | $1.6B |
| March 31, 2026 | $50.2B | 2.6% | $8.00 | $4.1B |
| December 31, 2025 | $49.7B | 9.5% | $2.54 | −$209M |
| September 30, 2025 | $50.7B | 12.4% | $5.32 | $775M |
| June 30, 2025 | $49.8B | 13.4% | $7.72 | $1.8B |
| March 31, 2025 | $48.9B | 14.8% | $9.61 | $821M |
| December 31, 2024 | $45.4B | 6.6% | $1.87 | $384M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $51.6B: Claude 62%, Gemini 88%, Mistral 35%
- Diluted earnings per share are at least $2.54: Claude 55%, Gemini 98%, Mistral 90%
- Free cash flow for the quarter is above zero: Claude 72%, Gemini 65%, Mistral 70%
20 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.